Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non–Small-Cell Lung Cancer With Brain Metastases

Clinical Question

Is up-front whole-brain radiotherapy required to treat multiple brain metastases from non–small-cell lung cancer when highly active targeted therapies are available?

Clinical Application

Patients withEGFR-mutant orALK-positive non–small-cell lung cancer with brain metastases now have the potential to achieve a prolonged survival. Through use of highly active targeted therapies, whole-brain...